Pregled bibliografske jedinice broj: 660965
Arsenic trioxide and rapamycin in acute myeloid leukemia (AML): potential synergistic effects
Arsenic trioxide and rapamycin in acute myeloid leukemia (AML): potential synergistic effects // Periodicum biologorum, Vol 115, Suppl 2, 2013. - 3. Congress of Croatian Physiological Society and 1. Regional Congress of the Physiological Societies / Vitale, Branko (ur.).
Zagreb, 2013. (poster, međunarodna recenzija, sažetak, znanstveni)
CROSBI ID: 660965 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Arsenic trioxide and rapamycin in acute myeloid leukemia (AML): potential synergistic effects
Autori
Dembitz, Vilma ; Lalić, Hrvoje ; Ostojić, Alen ; Vrhovac, Radovan ; Višnjić, Dora
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Izvornik
Periodicum biologorum, Vol 115, Suppl 2, 2013. - 3. Congress of Croatian Physiological Society and 1. Regional Congress of the Physiological Societies
/ Vitale, Branko - Zagreb, 2013
Skup
3. Congress of Croatian Physiological Society and 1. Regional Congress of the Physiological Societies
Mjesto i datum
Rijeka, Hrvatska, 13.09.2013. - 15.09.2013
Vrsta sudjelovanja
Poster
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
arsenic trioxide; rapamycin; acute myeloid leukemia
Sažetak
Arsenic trioxide (As2O3) is used together with the differentiative agent all-trans retinoic acid (ATRA) in the treatment of acute promyelocytic leukemia (APL), a subtype of AML. As2O3 has also shown some promising proapoptotic effects on other AML subtypes in vitro, but the used doses were potentially toxic in vivo. To test whether antiproliferative effects of lower doses of As2O3 could be enhanced by addition of mTOR inhibitor rapamycin, we incubated AML cell lines and primary samples isolated from peripheral blood of 4 representative patients (APL, de novo AML, relapsed AML, secondary AML) with As2O3, ATRA, rapamycin and their combination. After 96-hours incubation, rapamycin potentiated antiproliferative effects of lower doses of As2O3 in non-APL AML cell lines without affecting the expression of differentiation marker CD11b. As2O3 also reduced the viability of primary AML blasts, except in the case of secondary AML that was clinically shown to be refractory to chemotherapy. The reduction in cell number both in APL and non- APL samples was even greater when rapamycin or ATRA were added in combination with As2O3 which indicates that these agents might act in synergy. Presented results show that combination of As2O3 with rapamycin might have some therapeutic potential in non-APL AML.
Izvorni jezik
Engleski
Znanstvena područja
Temeljne medicinske znanosti, Kliničke medicinske znanosti
POVEZANOST RADA
Projekti:
044-0000000-3455 - Dijagnostika i terapija infekcija kod imunokompromitiranih bolesnika
108-1081347-1448 - Uloga PLC i Akt u staničnom ciklusu i diferencijaciji leukemija (Višnjić, Dora, MZOS ) ( CroRIS)
108-1081873-1893 - Prognostički faktori, dijagnostika i terapija hemoblastoza (Jakšić, Branimir, MZOS ) ( CroRIS)
Ustanove:
Medicinski fakultet, Zagreb
Citiraj ovu publikaciju:
Časopis indeksira:
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus